Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;28(11):1177-1183.
doi: 10.1007/s11916-024-01283-x. Epub 2024 Jun 27.

Pain Related Quality of Life in Neurofibromatosis Type 1: A Narrative Review

Karina Stech  1 , Behnum Habibi  2
Affiliations
Review

Pain Related Quality of Life in Neurofibromatosis Type 1: A Narrative Review

Karina Stech et al. Curr Pain Headache Rep. 2024 Nov.

Abstract

Purpose of review: The purpose of this narrative review is to summarize pain symptomatology and mechanisms in neurofibromatosis type 1 (NF1), discuss the pain related quality of life impacts of NF1, and discuss the literature exploring interventions to improve quality of life.

Recent findings: Chronic pain in NF1 is described as headache and non-headache pain. The literature describes mechanisms contributing to neuronal hyperexcitability in the setting of reduced neurofibromin as key contributors to pain in NF1. Pain in NF1 negatively impacts quality of life with pain interference, depression, anxiety, and cognitive functioning acting as important mediators. Mitogen-activated protein kinase (MEK) inhibitors are pharmacologic agents that interfere with pain mechanisms. Mind-body interventions improve coping skills to improve quality of life. Chronic pain in NF1 is heterogeneous with negative impacts on quality of life. New developments in pharmacological and non-pharmacological interventions offer promising approaches to pain management and quality of life improvement. Additional research is necessary to validate the use of MEK inhibitors and mind-body interventions in the treatment of NF1.

Keywords: Chronic pain; MEK Inhibitor; Mind-Body Intervention; Neurofibroma; Pain Interference.

PubMed Disclaimer

References

    1. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet. 1999;89:1–6. - DOI - PubMed
    1. Le C, Bedocs PM, Neurofibromatosis. StatPearls Publishing. 2023. https://www.ncbi.nlm.nih.gov/books/NBK459329/ . Accessed April 1, 2024.
    1. Almuqbil M, Alshaikh FY, Altwaijri W, Baarmah D, Hommady RH, Alshaikh MY, Alammari F, Alhussain M, Almotawa R, Alqarni F, Kashgari A, Alkodair R, Alkhater JN, Alkhater LN, Alharthi SA, Alsadi MA, AlRumayyan A. Epidemiology and outcomes of neurofibromatosis type (NF-1): multicenter tertiary experience. J Multidisciplinary Healthc. 2024. https://doi.org/10.2147/JMDH.S454921 . - DOI
    1. Bellampalli SS, Khanna R. Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment. Pain. 2019. https://doi.org/10.1097/j.pain.0000000000001486 . - DOI - PubMed - PMC
    1. Créange A, Zeller J, Rostaing-Rigattieri S, Brugières P, Degos JD, Revuz J, Wolkenstein P. Neurological complications of neurofibromatosis type 1 in adulthood. Brain. 1999. https://doi.org/10.1093/brain/122.3.473 . - DOI - PubMed

MeSH terms

LinkOut - more resources